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Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). MS usually starts 
with a relapsing-remitting course (RRMS) that later converts into a secondary progressive phase (SPMS). 
While inflammation is considered predominating in RRMS, neurodegenerative processes are probably more 
important in SPMS. The pathophysiology of MS includes autoreactive inflammatory cells that invade the 
CNS, causing demyelination, oligodendrocyte loss, axonal damage, astrocyte activation and subsequently 
gliotic scars. Over the last decade the importance of neuronal/axonal damage has been re-discovered. 
Although, most extensive during progressive MS, it is also an early phenomenon and can be noticed already 
soon after MS onset. It is the main cause of CNS atrophy and irreversible disability in MS. Several studies 
indicate that MS immunomodulatory therapy reduces this process, at least during RRMS. The most 
apparent clinical effect of MS therapy is relapse reduction. 
 
The aim of this thesis was to investigate the relationship between inflammation, neuropathological 
processes and the clinical course of MS in order to identify biomarkers that could be useful for monitoring 
disease activity and therapy efficacy. The pathophysiological mechanisms behind clinical relapse were 
explored, including the possible role of T-cell mediated cytotoxicity. 
Patients with RRMS or SPMS were included and healthy blood donors served as controls. Serum and 
cerebrospinal fluid (CSF) were obtained at relapse, remission or progression. A sub-group of RRMS 
patients with acute relapse were followed-up repeatedly 5 and 15 weeks after relapse onset. Pro- and 
antiinflammatory cytokines, neurofilament light chain protein (NFL), a marker of axonal damage and glial 
fibrillary acidic protein (GFAP), an astrogliosis marker were analysed in CSF. T-cell mediated cytotoxicity 
was investigated by analysing granzyme A and B in serum and CSF and by mRNA gene expression analysis 
of peripheral T-cells. 
NFL in CSF was increased in all MS patients and showed a 10-fold increase during clinical relapse in 
relation to patients in remission and progression. The levels peaked after five weeks and were sustained for 
15 weeks. CSF-levels of GFAP had a strong correlation to the EDSS in MS-patients, with the strongest 
correlation in the SPMS group. IL-6 in CSF was higher in RRMS patients than SPMS and controls. CCL2 in 
CSF was lower in RRMS patients with the lowest level at ongoing relapse compared with controls. 
Granzyme A and B were increased in CSF at acute relapse and increased level of granzyme A were 
sustained for up to 3 months. 
 
Increased levels of NFL indicate a continuous axonal damage throughout the clinical course of MS with the 
most extensive damage during acute relapses. Increased levels of GFAP in MS, with a strong correlation to 
increasing disability, indicate that astrogliosis is more prominent during clinical progression. While 
demyelination is considered the pathophysiological hallmark of relapse development, our data suggests that 
axonal damage may be important in this process. Further, the change in the CSF levels of inflammatory 
markers (IL-6, CCL2) during relapses supports a relationship between inflammation and axonal damage. 
We also demonstrate that T-cell cytotoxicity within the CNS/CSF compartment might participate in the 
immunopathogenesis of clinical relapses. Prolonged increase of NFL and granzyme A levels in CSF after a 
relapse support an ongoing immunological attack even after apparent clinical remission suggesting a 
dissociation between immunological and clinical remission. 
 
In conclusion, NFL appears to be a marker for relapse and GFAP for clinical progression. Although our 
data suggests that these markers might be useful in monitoring disease activity and MS therapies, further 
studies are needed. Intense treatment of relapse and reduction in relapse frequency during 
immunomodulatory treatments probably decrease axonal damage which should be beneficial for a positive 
long term outcome 
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